Randomized study of ibrutinib versus ibrutinib plus rituximab (i versus iR) in patients with relapsed chronic lymphocytic leukemia (CLL)
Phase of Trial: Phase II
Latest Information Update: 03 Nov 2016
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms i versus iR
- 24 Jun 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 09 Dec 2014 Interim results of first 93 patients were presented at the 56th Annual Meeting and Exposition of the American Society of Hematology.